Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC)
European Journal of Cancer · 2026-11 · 248 · 118149
DOI: 10.1016/j.ejca.2026.118149 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von W. Park und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Park, W., Manji, G., Azad, N., Borazanci, E., Hecht, J., Musher, B., Sohal, D., Strickler, J., O’Hara, M., Spira, A., Botta, G., Florou, V., Parikh, A., Chiorean, G. E., Messersmith, W., Pant, S., DeYoung, R., Patel, H., Zheng, Y., & Wolpin, B. (2026). Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC). European Journal of Cancer, 248, 118149. https://doi.org/10.1016/j.ejca.2026.118149
Vancouver
Park W, Manji G, Azad N, Borazanci E, Hecht J, Musher B, et al. Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC). European Journal of Cancer. 2026;248:118149. doi:10.1016/j.ejca.2026.118149
BibTeX
@article{Park2026,
author = {Park, W. and Manji, G.A. and Azad, N.S. and Borazanci, E. and Hecht, J.R. and Musher, B.L. and Sohal, D. and Strickler, J. and O’Hara, M.H. and Spira, A. and Botta, G.P. and Florou, V. and Parikh, A. and Chiorean, Gabriela E. and Messersmith, W. and Pant, S. and DeYoung, R.A. and Patel, H. and Zheng, Y. and Wolpin, B.M.},
title = {Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC)},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {118149},
doi = {10.1016/j.ejca.2026.118149}
}
EUVIMED